Benzene Ring Bonded Directly To The Hetero Ring (e.g., Flavones, Etc.) Patents (Class 549/403)
-
Patent number: 8778986Abstract: The bioflavonoid luteolin reduces amyloid-? peptide (A?) generation. Luteolin is also a selective GSK-3 inhibitor that 1) decreases amyloidogenic ?-secretase APP processing, and 2) promotes presenilin-1 (PS1) carboxyl-terminal fragment (CTF) phosphorylation. GSK-3? activity is essential for both PS1 CTF phosphorylation states and PS1-APP interaction. To validate The findings were validated in vivo, using a Tg2576 Alzheimer's Disease model system. Luteolin treatment decreased soluble A? levels, reduced GSK-3 activity, and disrupted PS1-APP association.Type: GrantFiled: January 25, 2008Date of Patent: July 15, 2014Assignee: University of South FloridaInventors: Jun Tan, Doug Shytle, Kavon Rezai-Zadeh
-
Publication number: 20140186277Abstract: The RhoE GTPase pathway has been identified as a target for screening and treatment methods for the prevention and/or reduction of short- and long-term UVB-induced skin damage, e.g., the prevention and/or reduction of UVB-induced wrinkles. The invention thus features screening and treatment methods for prevention or reduction of UVB-induced skin damage, and related compositions, e.g., cosmetic compositions.Type: ApplicationFiled: September 5, 2013Publication date: July 3, 2014Applicants: Shiseido Co., Ltd., The General Hospital CorporationInventors: Sam W. Lee, Lakshmi Raj, Anna I. Mandinova, Haruhi Iwaki, Yuji Katsuta, Jotaro Nakanishi
-
Publication number: 20140186328Abstract: The present invention provides neuroprotective polyphenol compounds, which can be synthetic analogs of fisetin, baicalein or chlorogenic acid, that maintain neuroprotective, anti-inflammatory, glutathione promoting, and/or antioxidant properties. The neuroprotective polyphenol compounds are useful for promoting, enhancing and/or increasing neuron protection, growth and/or regeneration. The polyphenol compounds further find use for increasing and or maintaining intracellular glutathione (GSH) levels. The polyphenol compounds are also useful for treating, preventing, mitigating and/or delaying neurodegenerative conditions, including diabetes, Parkinson's disease, Huntington's disease, Alzheimer's disease, non-Alzheimer's dementias, multiple sclerosis, traumatic brain injury, spinal cord injury or ALS.Type: ApplicationFiled: February 5, 2014Publication date: July 3, 2014Applicant: Salk Institute for Biological StudiesInventors: David R. Schubert, Pamela A. Maher, Chandramouli Chiruta
-
Patent number: 8759548Abstract: The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same.Type: GrantFiled: February 10, 2011Date of Patent: June 24, 2014Assignee: N30 Pharmaceuticals, Inc.Inventors: Xicheng Sun, Jian Qiu
-
Patent number: 8742141Abstract: The present invention provides compounds and methods of inhibiting and treating metastatic prostate cancer. The compounds include MEK4 inhibitors. In another aspect the invention provides methods of identifying inhibitors of metastatic prostate cancer by screening for inhibitors of MEK4.Type: GrantFiled: July 1, 2013Date of Patent: June 3, 2014Assignee: Northwestern UniversityInventors: Raymond C. Bergan, Karl A. Scheidt
-
Publication number: 20140148504Abstract: The present invention relates to a novel use of a flavone-based compound or a Kaempferia parviflora extract comprising the same. More particularly, the present invention relates to a composition for wrinkle improvement, anti-aging and skin elasticity enhancement or a composition for skin moisturization, which comprises a flavone-based compound or a Kaempferia parviflora extract comprising the same as an active ingredient. The composition of the present invention is very effective in inhibiting the activity of Collagenase-1 (MMP-1) and promoting the synthesis of collagen. Therefore, the composition of the present invention is useful for wrinkle improvement, anti-aging, skin elasticity enhancement, and skin moisturization via the inhibition of moisture loss from the skin.Type: ApplicationFiled: July 19, 2013Publication date: May 29, 2014Applicant: Industry-Academic Cooperation Foundation, Yonsei UniversityInventors: Jae Kwan Hwang, Jaekyung Kim
-
Publication number: 20140141510Abstract: The present invention relates to the use of a compound which inhibits the activity of MKK4 as a medicament for the treatment of a patient suffering from an impaired liver function, to the use of a compound as a medicament for the treatment of liver failure, including acute/fulminant or chronic liver failure and/or for increasing the regeneration of liver tissue in a patient.Type: ApplicationFiled: April 10, 2012Publication date: May 22, 2014Applicants: MEDIZINISCHE HOCHSCHULE HANNOVER, HELMHOLTZ ZENTRUM FUER INFEKTIONSFORSCHUNG GMBHInventors: Lars Zender, Torsten Wuestefeld
-
Patent number: 8716497Abstract: A method for preparing an enantiomeric chromane, by asymmetrically hydrogenating a chromene compound in the presence of an Ir catalyst having a chiral ligand. The method includes the enantioselective preparation of enantiomeric equol. A preferred Ir catalyst has a chiral phosphineoxazoline ligand. Enantiomeric chromanes of high stereoselective purity can be obtained.Type: GrantFiled: September 10, 2012Date of Patent: May 6, 2014Assignees: Children's Hospital Medical Center, Ausio Pharmaceuticals, Inc.Inventors: Kenneth David Reginald Setchell, Victor Dmitrievich Sorokin
-
Patent number: 8710097Abstract: Multidrug resistance (MDR) is a major problem in cancer chemotherapy. The best characterized resistance mechanism is the one mediated by the over-expression of drug efflux transporters, permeability-glycoprotein (P-gp), which pump a variety of anticancer drugs out of the cells, resulting in lowered intracellular drug accumulation. A series of flavonoid dimers are developed in this invention, which are linked together by linker groups of various lengths. These flavonoid dimers are found to be efficient P-gp modulators that increase cytotoxicity of anticancer drugs in vitro and dramatically enhance their intracellular drug accumulation. It is found that the flavonoid dimers of this invention is also useful in reducing drug resistance in treating parasitic diseases.Type: GrantFiled: May 9, 2007Date of Patent: April 29, 2014Assignees: The Hong Kong Polytechnic University, McGill UniversityInventors: Tak-Hang Chan, Larry Ming-Cheung Chow
-
Patent number: 8697891Abstract: Novel substituted chroman derivatives and intermediate compounds, compositions containing same, methods for their preparation and uses thereof as therapeutic agents particularly as anti-cancer and chemotherapeutic selective agents are described.Type: GrantFiled: November 10, 2011Date of Patent: April 15, 2014Assignee: Marshall Edwards, Inc.Inventors: Andrew Heaton, Alan James Husband
-
Publication number: 20140099370Abstract: The present invention relates to biodegradable polymers (e.g., polyesters and polyester amides) derived from functionalized biologically active compounds that can provide site specific delivery of bioactive compounds upon biodegradation in a controlled manner.Type: ApplicationFiled: September 24, 2013Publication date: April 10, 2014Applicant: BEZWADA BIOMEDICAL, LLCInventor: Rao S Bezwada
-
Publication number: 20140096780Abstract: Isolated O-methylated flavonoid compounds and mixtures of o-methylated flavonoid compounds derived from a plant of the Nicotiana species and methods of obtaining such compounds are provided. The o-methylated flavonoids can be combined with tobacco materials to produce tobacco products (e.g., smoking articles) to enhance the sensory characteristics thereof. The o-methyl flavonoids can alternatively be combined with non-tobacco materials for dietary supplement and/or pharmaceutical use.Type: ApplicationFiled: October 9, 2012Publication date: April 10, 2014Applicant: R.J. REYNOLDS TOBACCO COMPANYInventor: Anthony Richard Gerardi
-
Patent number: 8686028Abstract: The present invention relates to novel substituted benzfurochromenes and related compounds having the general formula (I), salts and chiral, achiral derivatives thereof; wherein R1, R2, R3, R4, R5, R6, R7, R8 are independently selected from the groups consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkoxyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkylthio, optionally substituted amino, optionally substituted acylamino, optionally substituted arylamino, optionally substituted acylthio, optionally substituted acyl, optionally substituted aroyl, optionally substituted acyloxy, optionally substituted thioamido, halogens, nitriles, esters, hydroxy, mercapto, carbontrifluoride, nitro but not limited to this; wherein R1R2 or R2R3 or R6R7 may be connected and form either a five membered ring or a six membered ring such as optionally substituted furan, optionally substituted dihydrofuran, optionally substitutedType: GrantFiled: May 14, 2009Date of Patent: April 1, 2014Assignee: Council of Scientific & Industrial ResearchInventors: Atul Goel, Amit Kumar, Sumit Chaurasia, Divya Singh, Abnish Kumar Gautam, Rashmi Pandey, Ritu Trivedi, Man Mohan Singh, Naibedya Chattopadhyay, Lakshmi Manickavasagam, Girish Kumar Jain, Anil Kumar Dwivedi
-
Patent number: 8673966Abstract: Disclosed are novel isoflavone derivatives having the structure of Formula I: which are ALDH-2 inhibitors, useful for treating a patient in need thereof, for dependence upon drugs of addiction, for example addiction to dopamine-producing agent such as cocaine, morphine, amphetamines, nicotine, and alcohol.Type: GrantFiled: August 30, 2012Date of Patent: March 18, 2014Assignee: Gilead Sciences, Inc.Inventors: Michael Graupe, Chandrasekar Venkataramani, Jeff Zablocki
-
Patent number: 8669381Abstract: The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same.Type: GrantFiled: June 7, 2013Date of Patent: March 11, 2014Assignee: N30 Pharmaceuticals, Inc.Inventors: Xicheng Sun, Jian Qiu, Jan Wasley
-
Publication number: 20140031567Abstract: The present invention relates to a method for converting fustin into fisetin through the gas bubbling treatment of a solution containing fustin. Rhus verniciflua Stokes extracts having high content of Fisetin may be used as anticancer agents, anticancer and cancer prevention food products, and health functional foods due to the excellent bioactivity thereof.Type: ApplicationFiled: September 11, 2013Publication date: January 30, 2014Applicant: AZI COMPANY LTD.Inventors: Sang-Jae Park, Sung-Pil Kwon, Won-Cheol Choi
-
Publication number: 20140031421Abstract: The present invention provides synthetic processes for preparing racemic and/or optically pure epicatechin, epigallocatechin and related polyphenols as such or as their variously functionalized derivatives. A principle objective of the disclosure is to provide a new and useful method of synthesis to obtain polyphenols in isomerically pure and/or racemic forms.Type: ApplicationFiled: January 24, 2012Publication date: January 30, 2014Applicant: SPHAERA PHARMA PTE. LTD.Inventors: Sundeep Dugar, Dinesh Mahajan, Pantelis Peter Giannousis, Vijay Singh, Kamal Kishore Kapoor
-
Publication number: 20140018552Abstract: The present invention provides an AGE inhibitor and a health functional food for inhibiting an occurrence of diabetic complications. Particularly, the present invention comprises a compound selected from the group consisting of mulberrofuran G, mulberrofuran K, kuwanon G, kuwanon Z, oxyresveratrol, 2?,4?,5,7-tetrahydroxyflavanone, morusignin L and dihydromorin isolated from Morus Bark as an active ingredient. The compounds disclosed above inhibit the production of AGE which is a causative substance of diabetic complications. Thus, the compounds could be used as an AGE inhibitor and a health functional food for inhibiting diabetic nephropathy, diabetic retinopathy and diabetic neuropathy.Type: ApplicationFiled: March 26, 2012Publication date: January 16, 2014Applicant: Dong Wha Pharm. Co., Ltd.Inventors: Hwan Bong Chang, Joobyoung Yoon, Hyun Yong Lee, Hyun Sik Choi, Hyung Bok Lee
-
Patent number: 8623910Abstract: A method of treatment of mucopolysaccharidosis, the method including administering to a patient in the need of such treatment—a therapeutically effective amount of a natural isoflavone of formula (I), a derivative thereof, or a pharmaceutically acceptable salt thereof. A pharmaceutical composition including a pharmaceutically acceptable excipient; and a natural isoflavone of formula (I), a derivative thereof, or a pharmaceutically acceptable salt thereof, the natural isoflavone, the derivative thereof, or the pharmaceutically acceptable salt thereof being in a therapeutically effective amount for the treatment of mucopolysaccharidosis.Type: GrantFiled: March 29, 2012Date of Patent: January 7, 2014Assignee: Instytut FarmaceutycznyInventors: Grzegorz Grynkiewicz, Grzegorz Wegrzyn, Barbara Szechner, Wieslaw Szeja, Anna Tylki-Szymanska, Alicja Wegrzyn, Joanna Jakobkiewicz-Banecka, Sylwia Baranska, Barbara Czartoryska, Ewa Piotrowska
-
Publication number: 20130345300Abstract: The present invention relates to the use of compounds which are capable of producing a cooling sensation when they are brought into contact with the human body. In particular, the present invention relates to the use of compounds modulating TRPM8, and optionally to the use of compounds selectively exhibiting agonist activity at the TRPM8 channel. Such compounds have applications in many fields, particularly in oral and personal hygiene products and foodstuffs, but also in pharmaceutical composition products, cosmetics, textile products and packaging products. The present invention further relates to products containing such compounds and to the medical use of such compounds.Type: ApplicationFiled: March 8, 2012Publication date: December 26, 2013Applicant: B.R.A.I.N. Biotechnology Research and Information Network AGInventors: Michael Krohn, Holger Zinke
-
Publication number: 20130296582Abstract: The present invention provides compounds and methods of inhibiting and treating metastatic prostate cancer. The compounds include MEK4 inhibitors. In another aspect the invention provides methods of identifying inhibitors of metastatic prostate cancer by screening for inhibitors of MEK4.Type: ApplicationFiled: July 1, 2013Publication date: November 7, 2013Inventors: Raymond C. Bergan, Karl A. Scheidt
-
Patent number: 8569526Abstract: The invention relates to a method for carrying out an oxidation reaction for producing a product by heating a reaction medium containing a reactant and oxygen or an oxygen carrier in a reactor, wherein the reaction medium is brought into contact with a solid heating medium which may be heated by electromagnetic induction, which is surrounded by the reaction medium. The heating medium is heated by electromagnetic induction using an inductor, wherein an oxidation reaction is carried out on the first reactant to give a product and the product is separated from the heating medium. The inductor preferably generates an alternating field with a frequency in the range 1 to 100 kHz, preferably in the range 10 to 80 kHz and in particular up to 50 kHz.Type: GrantFiled: August 16, 2011Date of Patent: October 29, 2013Assignee: Henkel AG & Co. KGaAInventors: Carsten Friese, Andreas Kirschning, Sascha Volkan Ceylan
-
Publication number: 20130274320Abstract: The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same.Type: ApplicationFiled: June 7, 2013Publication date: October 17, 2013Inventors: Xicheng Sun, Jian Qiu, Jan Wasley
-
Patent number: 8546376Abstract: The invention relates to a series of compounds with particular activity as inhibitors of the serine-threonine kinase AKT. Also provided are pharmaceutical compositions comprising same as well as methods for treating cancer.Type: GrantFiled: September 17, 2010Date of Patent: October 1, 2013Assignee: Almac Discovery LimitedInventors: Mark Peter Bell, Timothy Harrison, Sumita Bhattacharyya, James Samuel Shane Rountree, Frank Burkamp, Stephen Price, Calum MacLeod, Richard Leonard Elliott, Phillip Smith, Toby Jonathan Blench, Colin Roderick O'Dowd, Lixin Zhang, Graham Peter Trevitt, Hazel Joan Dyke
-
Publication number: 20130251730Abstract: Suggested is a compound of the formula (X) or any salt of a compound of the formula (X) or any mixture containing or consisting of two or more different compounds of the formula (X), two or more different salts of compounds of the formula (X) or one or more different compounds of the formula (X) and one or more different salts of compounds of the formula (X), wherein for R1, R2 and R3 independently of one another in every compound of the formula (X) the following applies: R1 means hydrogen or methyl, R2 means an organic residue with 5 carbon atoms and one oxygen atom or none and R3 means an organic residue with 10 carbon atoms and one or more oxygen atoms, or R1 and R2 together with the carbon atoms in positions 4 and 5 and the oxygen atom bound to the carbon atom in position 4 form a ring and comprise 5 carbon atoms and one oxygen atom or none, and R3 means an organic residue with 10 carbon atoms and one or more oxygen atoms, for use in a method for the prophylaxis and/or treatment of inflammation.Type: ApplicationFiled: March 1, 2013Publication date: September 26, 2013Applicant: Symrise AGInventors: Jakob Ley, Katharina Reichelt, Marcus Götz, Maria Blings, Veronika Somoza, Jessica Walker, Joel Michael Walker
-
Publication number: 20130231325Abstract: Disclosed are novel isoflavone derivatives having the structure of Formula I: which are ALDH-2 inhibitors, useful for treating a patient in need thereof, for dependence upon drugs of addiction, for example addiction to dopamine-producing agent such as cocaine, morphine, amphetamines, nicotine, and alcohol.Type: ApplicationFiled: August 30, 2012Publication date: September 5, 2013Applicant: Gilead Sciences. Inc.Inventors: Michael Graupe, Chandrasekar Venkataramani, Jeff Zablocki
-
Publication number: 20130231492Abstract: Flavone derivatives, preparative method of the derivatives and use thereof as medicaments for treating diabetes. The structure of the derivatives is presented by formula 1: In the structure, R1 and R2, which are identical or not, represent hydrogen atom, halogen, cyano, hydroxyl, trifluoromethyl, thio-methyl, benzyloxy, C1-C8 linear chain or branch chain alkyl, C1-C8 linear chain or branch chain alkoxy. The pharmacological test indicates that the flavone derivatives can significantly increase the glucose consumption of Hep-G2 cell with insulin resistance activity, promote translocation of glucose transporter 4 of skeletal muscle cells (L6GLUT4myc) at different level, and significantly increase glucose intake and utilization by cells.Type: ApplicationFiled: November 12, 2010Publication date: September 5, 2013Inventors: Hongquan Duan, Nan Qin, Wenyan Niu, Meina Jin, Lihuan Shi, Ying Chen
-
Publication number: 20130225530Abstract: The present invention relates to a pharmaceutical composition for use as a medicament for the treatment or prophylaxis of cardiac hypertrophy, comprising at least one compound of formula (I), wherein: R1 is e.g. hydrogen, —CH3, R2 is e.g. hydrogen, —CH3, R4 is hydrogen, —OH, —NH2; R5 is hydrogen, —OH; R6 is hydrogen, —OH; R3 is e.g. —OCH3 or a pharmaceutically acceptable salt, and at least one pharmaceutical excipient.Type: ApplicationFiled: July 6, 2011Publication date: August 29, 2013Applicant: DKFZ DEUTSCHES KREBSFORSCHUNGSZENTRUMInventors: Min Li-Weber, H. Peter Krammer, Gernot Polier
-
Patent number: 8501970Abstract: The invention relates to a novel process for the preparation of C-4 coupled flavonoids, proanthocyanidins and analogues thereof. According to a specific application of the invention, there is provided a method for the preparation of proanthocyanidins and proanthocyanidin analogues.Type: GrantFiled: June 5, 2009Date of Patent: August 6, 2013Assignee: University of the Free stateInventors: Jan Hendrik Van Der Westhuizen, Matthew Achilonu, Susanna Lucia Bonnet
-
Publication number: 20130184475Abstract: Provided are compositions for treatment of cancers, including breast cancer, comprising at least one novel daidzein analog, as well as methods of using the same for preventing or treating cancer or tumor growth.Type: ApplicationFiled: July 8, 2011Publication date: July 18, 2013Applicants: THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND, XAVIER UNIVERSITY OF LOUISIANNA, UNITED STATES DEPARTMENT OF AGRICULTUREInventors: Guangdi Wang, Matthew E. Burow, Stephen M. Boue, Thomas E. Wiese, Quan Jiang
-
Patent number: 8481760Abstract: The present invention provides compounds and methods of inhibiting and treating metastatic prostate cancer. The compounds include MEK4 inhibitors. In another aspect the invention provides methods of identifying inhibitors of metastatic prostate cancer by screening for inhibitors of MEK4.Type: GrantFiled: October 13, 2009Date of Patent: July 9, 2013Assignee: Northwestern UniversityInventors: Raymond C. Bergan, Karl A. Scheidt
-
Patent number: 8481590Abstract: The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same.Type: GrantFiled: February 12, 2010Date of Patent: July 9, 2013Assignee: N30 Pharmaceuticals, Inc.Inventors: Xicheng Sun, Jian Qiu, Jan Wasley
-
Patent number: 8476313Abstract: Compounds and methods useful for treating and prevention of cancer, particularly hormone-dependent breast cancer. Provided are compounds of formula I: wherein X is selected from O, N, S, SO, SO2, and S(CH2)n, wherein n=1-10; R1 and R2 may be the same or different and are selected from H, OH, OCH3, OCH2CH3, OCH2C6H5, NH2, NHCH3, N(CH3)2, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, C(CH3)3, NO2, F, Cl, Br, CF3, SH, SCH3, SCH2CH3, OCOCH3, OCOC(CH3)3, OCOCH2COOH, and CN; and R3 is a nitrogen-containing heterocyclic ring. Also provided are method for treating or preventing cancer in a subject by administering a therapeutically effective amount of a heteroaryl-containing isoflavone, or a pharmaceutically acceptable salt or prodrug thereof, to a subject in need of treatment.Type: GrantFiled: May 26, 2009Date of Patent: July 2, 2013Assignee: The Ohio State University Research FoundationInventors: Robert W. Brueggemeier, Young-Woo Kim, John C. Hackett
-
Publication number: 20130137694Abstract: There is provided modulators of Nrf2 protein which comprises a compound which binds at least one of the BTB domain, IVR domain and Kelch domain of Keap1 protein, activating or inhibiting Nrf2. There is also provided pharmaceutical compositions containing the modulators, as well as uses and method of use of the modulators for the treatment of conditions.Type: ApplicationFiled: May 31, 2011Publication date: May 30, 2013Inventors: Gerald Batist, Jian Hui Wu
-
Publication number: 20130136811Abstract: Compositions containing four-herb extract combination or Wogonin are useful in methods for the reduction of pain. A four-herb combination is used to treat pain as well as reduce or prevent epileptic seizures.Type: ApplicationFiled: May 26, 2011Publication date: May 30, 2013Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventor: Steven C. Schachter
-
Publication number: 20130129808Abstract: A medical product containing either an active ingredient of propolis which is a natural antibiotic or a grapefruit seed extract, and a manufacturing method thereof are provided. The medical product is impregnated with a solution of CAPE (caffeic acid phenethyl ester) or pinocembrin, which is an active ingredient of propolis having antibacterial effects, to increase the antibacterial activity of the medical product due to antibacterial compounds contained in the active component, or the medical product is impregnated with a solution of a grapefruit seed extract such that the extract can exhibit antibacterial activity in the medical product.Type: ApplicationFiled: January 12, 2012Publication date: May 23, 2013Applicant: Korea Institute of Ceramic Engineering and TechnologyInventors: Jeong Ho CHANG, Hye Sun LEE, Jin Hyung LEE
-
Publication number: 20130131160Abstract: The present invention discloses a use of hesperetin or a hesperetin-containing plant extract in the manufacture of a product for improving and/or promoting skin microcirculation, or for eliminating and/or alleviating diseases or conditions associated with poor skin microcirculation. The present invention also discloses a composition comprising an effective amount of hesperetin or a hesperetin-containing plant extract, and to a method for improving and/or promoting skin microcirculation, or eliminating and/or alleviating diseases or conditions associated with poor skin microcirculation, by using hesperetin. The skin microcirculation of the present invention is preferably eye skin microcirculation.Type: ApplicationFiled: June 15, 2011Publication date: May 23, 2013Applicant: Natural Medicine Institute of Zhejiang Yangshengta Co., Ltd.Inventors: Liu Hu, Hongying Lan
-
Publication number: 20130131328Abstract: Process for fractioning and refining natural products obtainable from waste vegetal material and particularly from artichoke (Cynara scolymus) production or from other plants of the Cynara genus such as the cultivated or wild cardoon. The process is based on the use of membrane separation technologies envisaging a tangential microfiltration (MF) phase on the raw decoction, followed by tangential ultrafiltration (UF) on the previous MF permeate and reverse osmosis (RO) on the UF permeate, in order to obtain a retentate rich in concentrated active ingredients and a permeate consisting of ultrapure water that is recycled for the preparation of the decoction. The process enables obtaining purified extracts of high biological valence to be used in the pharmaceutical industry, in the nutraceutic sector, in the cosmetics industry and for innovative products in the food industry.Type: ApplicationFiled: November 5, 2012Publication date: May 23, 2013Applicants: ISR ECOINDUSTRIA S.R.L.Inventors: ISR Ecoindustria S.R.L., Massimo Pizzichini, Annalisa Romani
-
Publication number: 20130116450Abstract: A method for preparing an enantiomeric chromane, by asymmetrically hydrogenating a chromene compound in the presence of an Ir catalyst having a chiral ligand. The method includes the enantioselective preparation of enantiomeric equol. A preferred Ir catalyst has a chiral phosphineoxazoline ligand. Enantiomeric chromanes of high stereoselective purity can be obtained.Type: ApplicationFiled: September 10, 2012Publication date: May 9, 2013Applicants: GIRINDUS AMERICA, INC., CHILDREN'S HOSPITAL MEDICAL CENTERInventors: Kenneth David Reginald SETCHELL, Victor Dmitrievich Sorokin
-
Publication number: 20130116138Abstract: Described herein are small peptide domains and consensus sequences that bind small target molecules of industrial importance, e.g., metals such as nickel, ? carotene, and isoflavones such as genistein. Also described are fusion proteins containing such binding domains fused to proteins or to peptide domains like GST or GBD that bind other ligands and can be used to immobilize the target binding domain on a support. One class of fusion proteins that is useful in industrial settings are fusions that contain concatemers of target binding domains, which increases the binding equivalents per molecule.Type: ApplicationFiled: January 28, 2011Publication date: May 9, 2013Applicants: Archer-Daniels-Midland Company, Iowa State University Research Foundation, Inc.Inventors: Thomas P. Binder, Aragula Gururaj Rao, Yasufumi Yamamoto, Paul Hanke
-
Publication number: 20130096189Abstract: One of the major hair concerns for both men and women is that of hair loss. For men the most obvious manifestation of this is male pattern baldness known as alopecia areata. However hair shedding resulting in hair thinning is also a concern for both men and women. Individuals suffering hair loss often experience psychological disadvantages, for example social phobia, anxiety, and depression, due to their change in appearance. This invention relates to a hair care composition comprising glabranin or a derivative thereof. The invention also relates to a cosmetic method for increasing hair fibre diameter, stimulating hair growth, retaining hair or reducing hair loss, stimulating hair follicle growth in anagen or telogen phases, increasing hair fibre density and preventing or treating alopecia.Type: ApplicationFiled: July 4, 2011Publication date: April 18, 2013Inventors: Ranjit Kaur Bhogal, Julia Sarah Rogers
-
Publication number: 20130096209Abstract: The present invention provides edible compositions comprising a compound of the present invention, food products comprising such edible compositions and methods of preparing such food products. The present invention also provides methods of reducing the amount of NaCl in a food product, methods of reducing the sodium intake in a diet, and methods of reducing bitter taste in a food product.Type: ApplicationFiled: April 15, 2011Publication date: April 18, 2013Applicants: Kraft Foods Global Brands LLC, Chromocell CorporationInventors: David Hayashi, William P. Jones, Jane V. Leland, Peter H. Brown, Joseph Gunnet, Daniel Lavery, Louise Slade, Kambiz Shekdar, Jessica Langer
-
Publication number: 20130079294Abstract: The present invention relates to flavonoids isolated from Euphorbia cuneata, a method for their isolation, extracts from Euphorbia cuneata and a pharmaceutical composition comprising the flavonoids or the extracts or both of them for a use as anti-ulcer agent.Type: ApplicationFiled: July 9, 2012Publication date: March 28, 2013Applicant: KING SAUD UNIVERSITYInventors: Amani S. Awaad, Reham Moustafa El-Meligy
-
Publication number: 20130079393Abstract: Isoflavone fatty acid ester derivatives of formula (I) or (II), the preparation method thereof and the pharmaceutical compositions containing such compounds are disclosed. The uses of such compounds in preparation of medicaments for preventing or treating hyperlipidemia, obesity or type II diabetes are also disclosed.Type: ApplicationFiled: March 1, 2010Publication date: March 28, 2013Applicant: CHINA PHARMACEUTICAL UNIVERSITYInventors: Hua Xiang, Wei Zhao, Hong Xiao, Yao Yao, Renling Ma, Lei Qian, Xiaobo Li, Qidong You, Qingjiang Liao
-
Method for resolution of a mixture of pinocembrin optical isomers, especially a pinocembrin racemate
Patent number: 8399691Abstract: The present invention relates to a method for resolution of a mixture of pinocembrin optical isomers, in particular a pinocembrin racemate, using a chiral primary amine or a chiral sulfinamide. The present invention also relates to a (R)-(+)-pinocembrin obtained by the method.Type: GrantFiled: November 7, 2008Date of Patent: March 19, 2013Assignees: CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd., Institute of Materia Medica, Chinese Academy of Medical SciencesInventors: Song Wu, Guanhua Du, Yue Yuan, Qingyun Yang, Mei Gao, Yan Qi, Yuanfeng Tong, Yuehua Wang -
Patent number: 8399511Abstract: Two crystalline forms of pinocembrin of formula (I): ? and ?, their preparation and their use for manufacture of pharmaceutical compositions. There exists difference between them in bioavailability. They are used for treating and preventing cerebral ischemic diseases by protective action of neurovascular unit, and enhancing blood drug level in vivo.Type: GrantFiled: November 13, 2008Date of Patent: March 19, 2013Assignees: CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd., Institute of Materia Medica, Chinese Academy of Medical SciencesInventors: Guanhua Du, Yang Lv, Song Wu, Ke Wang, Ying Chang, Zhihong Yang, Yuanfeng Tong, Mei Gao
-
Publication number: 20130064913Abstract: Disclosed are botanically based compositions and methods useful for the treatment of metabolic syndrome and diabetes type 2. Compositions, kits, and methods are additionally disclosed for means to augment the activity of identified glucose and insulin regulating drugs.Type: ApplicationFiled: June 1, 2012Publication date: March 14, 2013Applicant: Metaproteomics, LLCInventors: Matthew L. Tripp, John G. Babish, Jeffrey S. Bland, Amy J. Hall, Veera Konda, Linda M. Pacioretty
-
Publication number: 20130059907Abstract: A pharmaceutical composition for inhibiting cancer stem cells growth or carcinoma metastasis and an application thereof are disclosed. The pharmaceutical composition includes: a wogonin compound; and a pharmaceutically acceptable carrier. The application is the use of the wogonin compound to manufacture a medicament for inhibiting cancer stem cells growth or carcinoma metastasis.Type: ApplicationFiled: November 14, 2011Publication date: March 7, 2013Applicants: National Taiwan Normal UniversityInventors: Hsiu-Mei Hsieh, Chen-Yu Lee, Chih-Chien Shen, Tien-Chun Wang
-
Publication number: 20130059384Abstract: Compositions and methods comprising bioenergetic agents for restoring the quality of aged oocytes, enhancing oogonial stem cells or improving derivatives thereof (e.g., cytoplasm or isolated mitochondria) for use in fertility-enhancing procedures, are described.Type: ApplicationFiled: April 13, 2012Publication date: March 7, 2013Applicants: PRESIDENT AND FELLOWS OF HARVARD COLLEGE, THE GENERAL HOSPITAL CORPORATIONInventors: JONATHAN L. TILLY, DAVID A. SINCLAIR
-
Publication number: 20130045935Abstract: This invention relates to bis-flavonoid compounds of formula Flavonoid-Linker-Y-Linker-Flavonoid, their synthesis and use for inhibiting multidrug resistance in chemotherapy and protozoan infection.Type: ApplicationFiled: May 3, 2011Publication date: February 21, 2013Inventors: Tak-Hang Chan, Larry Ming-Cheung Chow, Kin-Fai Chan, Iris Lai King Wong